Mineralys Therapeutics, Inc. (MLYS) stock
MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$14.48−0.05 (-0.34%)
Close on Nov 17, 2026Market cap $1.28BP/E –Yield –
Mineralys Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Mineralys Therapeutics's total assets was $667.85M at Jun 30, 2026. For fiscal 2025 it was $661.81M, up 221.4% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $661.81M | +221.4% |
| FY2024 | Dec 31, 2024 | $205.90M | -18.2% |
| FY2023 | Dec 31, 2023 | $251.64M | +119.9% |
| FY2022 | Dec 31, 2022 | $114.44M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $667.85M | +98.9% |
| Q1 FY2026 | Mar 31, 2026 | $652.86M | +83.9% |
| Q4 FY2025 | Dec 31, 2025 | $661.81M | +221.4% |
| Q3 FY2025 | Sep 30, 2025 | $599.95M | +123.6% |
| Q2 FY2025 | Jun 30, 2025 | $335.72M | +5.4% |
| Q1 FY2025 | Mar 31, 2025 | $354.94M | +2.2% |
| Q4 FY2024 | Dec 31, 2024 | $205.90M | -18.2% |
| Q3 FY2024 | Sep 30, 2024 | $268.25M | -3.4% |
| Q2 FY2024 | Jun 30, 2024 | $318.49M | +9.4% |
| Q1 FY2024 | Mar 31, 2024 | $347.25M | +13.3% |
| Q4 FY2023 | Dec 31, 2023 | $251.64M | +119.9% |
| Q3 FY2023 | Sep 30, 2023 | $277.56M | – |
| Q2 FY2023 | Jun 30, 2023 | $291.22M | – |
| Q1 FY2023 | Mar 31, 2023 | $306.44M | – |
| Q4 FY2022 | Dec 31, 2022 | $114.44M | – |
See a number that looks wrong?